IRIS
PARISI, Alessandro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.021
AS - Asia 1.940
EU - Europa 1.084
SA - Sud America 463
AF - Africa 85
OC - Oceania 4
Totale 5.597
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.939
SG - Singapore 561
VN - Vietnam 495
BR - Brasile 346
RU - Federazione Russa 336
CN - Cina 335
HK - Hong Kong 284
IT - Italia 269
FR - Francia 126
DE - Germania 89
IN - India 65
GB - Regno Unito 53
FI - Finlandia 47
AR - Argentina 38
BD - Bangladesh 37
MX - Messico 37
IE - Irlanda 35
NL - Olanda 34
CA - Canada 30
IQ - Iraq 24
CI - Costa d'Avorio 22
AT - Austria 21
EC - Ecuador 21
ID - Indonesia 20
ZA - Sudafrica 20
CO - Colombia 17
SE - Svezia 16
PK - Pakistan 15
JP - Giappone 14
ES - Italia 13
VE - Venezuela 13
PL - Polonia 10
KR - Corea 9
MA - Marocco 9
SA - Arabia Saudita 9
TR - Turchia 9
CL - Cile 8
EG - Egitto 8
PH - Filippine 8
PY - Paraguay 8
PE - Perù 7
UA - Ucraina 7
AE - Emirati Arabi Uniti 6
KE - Kenya 6
LT - Lituania 6
TW - Taiwan 6
DZ - Algeria 5
TH - Thailandia 5
TN - Tunisia 5
UZ - Uzbekistan 5
AU - Australia 4
BG - Bulgaria 4
IL - Israele 4
KZ - Kazakistan 4
LB - Libano 4
PA - Panama 4
AZ - Azerbaigian 3
BY - Bielorussia 3
CR - Costa Rica 3
JO - Giordania 3
NG - Nigeria 3
NP - Nepal 3
PR - Porto Rico 3
UY - Uruguay 3
AL - Albania 2
BO - Bolivia 2
JM - Giamaica 2
QA - Qatar 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BH - Bahrain 1
CH - Svizzera 1
CY - Cipro 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
IR - Iran 1
KG - Kirghizistan 1
KW - Kuwait 1
LY - Libia 1
MM - Myanmar 1
MU - Mauritius 1
MY - Malesia 1
MZ - Mozambico 1
OM - Oman 1
PT - Portogallo 1
RO - Romania 1
SI - Slovenia 1
SN - Senegal 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TG - Togo 1
ZW - Zimbabwe 1
Totale 5.597
Salva come PNG Salva come JPEG
Città #
Ashburn 679
Singapore 343
San Jose 298
Hong Kong 277
Ho Chi Minh City 174
Dallas 166
Hanoi 108
Beijing 90
Boardman 89
Lauterbourg 71
The Dalles 66
Hefei 61
Los Angeles 58
Council Bluffs 54
Moscow 52
Munich 41
Helsinki 36
Orem 35
Dublin 33
São Paulo 32
Da Nang 24
Santa Clara 24
Shenzhen 24
Abidjan 22
Buffalo 22
Chennai 21
Rome 21
Mexico City 19
New York 19
Nuremberg 19
Chandler 17
Chicago 17
Ancona 16
Montreal 16
Fairfield 15
Haiphong 14
London 14
Milan 14
Seattle 12
Shanghai 12
Tokyo 12
Zhengzhou 12
Brasília 11
Camerino 11
Vienna 11
Amsterdam 10
Denver 10
Des Moines 10
Turku 10
Houston 9
Hải Dương 9
Manchester 9
Warsaw 9
Washington 9
Can Tho 8
Frankfurt am Main 8
Jacksonville 8
New Delhi 8
Rio de Janeiro 8
Urbisaglia 8
Biên Hòa 7
Boston 7
Dhaka 7
Elk Grove Village 7
Johannesburg 7
Lima 7
Ninh Bình 7
Stockholm 7
Ann Arbor 6
Baghdad 6
Bari 6
Bogotá 6
Bologna 6
Erbil 6
Florence 6
Guangzhou 6
Medellín 6
Phoenix 6
Quito 6
Secaucus 6
Thái Bình 6
Asunción 5
Atlanta 5
Campinas 5
Cotia 5
Goiânia 5
Guayaquil 5
Lawrence 5
Miami 5
Mumbai 5
Nairobi 5
Naples 5
Princeton 5
Saint Louis 5
Salt Lake City 5
San Francisco 5
Seoul 5
Tashkent 5
Toronto 5
Belo Horizonte 4
Totale 3.543
Salva come PNG Salva come JPEG
Nome #
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature 186
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 156
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 128
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis 106
Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status 102
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 100
Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report 99
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 99
Pemigatinib in pazienti affetti da colangiocarcinoma localmente avanzato o metastatico con fusione o riarrangiamento di FGFR2 pretrattati: analisi congiunta degli studi di coorte multicentrici, osservazionali, "real-world" francese PEMI-BIL e italiano PEMI-REAL 98
Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers 96
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 96
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 95
The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings 95
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer 91
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? 89
Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis 86
First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience 86
Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study 86
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 86
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 85
Immunotherapy in Triple-Negative Breast Cancer 85
Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study 83
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 81
Evaluation of prognostic factors for survival in transverse colon cancer 81
Changes in clinical presentation, management, and survival outcomes in patients affected by colorectal cancer following COVID-19 pandemic 80
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer 80
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies 79
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 79
Communication in oncology between healthcare providers, patients, the scientific community, and the media: recommendations from the Italian Association of Medical Oncology (AIOM) 78
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 77
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 76
What is known about theragnostic strategies in colorectal cancer 76
Multimodality treatment in metastatic gastric cancer: From past to next future 73
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 73
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 73
Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort 72
The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer 71
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study 71
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study 70
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 69
Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption 69
The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference 67
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab 67
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry 67
The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients 67
Is it a new era for intrahepatic cholangiocarcinoma? 66
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer 66
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction 65
Timed-flat infusion of 5-fluorouracil with docetaxel and oxaliplatin as first-line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen 65
How to best exploit immunotherapeutics in advanced gastric cancer: Between biomarkers and novel cell-based approaches 63
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 61
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study 60
The emerging role of immunotherapy in the treatment of anal cancer 60
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 56
Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis 56
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: Preliminary report of the FAMI-L1 study 55
Time-Dependent COVID-19 Mortality in Patients with Cancer: An Updated Analysis of the OnCovid Registry 55
Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab 55
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 53
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A “snapshot” from clinical practice 53
A case of segmental hepatic necrosis complicating oxaliplatin and capecitabine chemotherapy: A case report and review of the literature 53
The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study 52
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 51
Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature 51
Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series 50
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 49
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice 48
Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study 47
Looking for a place for dose-dense TMZ regimens in GBM patients: An experience with MGMT exploratory evaluation 47
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study 45
Topical menthol for treatment of chemotherapy-induced peripheral neuropathy 44
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome 44
Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer 43
Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report 42
Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy 42
SEX-RELATED DIFFERENCES IN EFFICACY AND SAFETY OF IMMUNOTHERAPY IN HEPATOCELLULAR CARCINOMA: SYSTEMATIC REVIEW AND META-ANALYSIS OF LANDMARK PHASE III TRIALS AND VALIDATION IN ROUTINE CLINICAL PRACTICE 41
Where are we with treatment options after first line in small cell lung cancer?-Report of two opposite cases treated with CAPTEM regimen and possible perspectives 39
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 39
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 32
Into the storms: Organising oncological home care services during natural disasters and global pandemics 32
Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis 30
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 29
SHORT-COURSE RADIOTHERAPY FOR OLDER PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER AND UNFIT FOR CHEMOTHERAPY: THE SOFT STUDY 29
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 13
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study 7
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab 3
Clinically interpretable nomogram combining body composition and clinicopathological features for one year survival prediction in advanced solid tumors 2
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study 2
Preliminary report on advanced biliary cancer patients receiving multimodality treatment in the immunotherapy era: a real-world multicentre experience 2
Totale 5.826
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.427
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.427
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202110 0 0 0 0 0 0 0 0 0 4 2 4
2021/202231 0 2 0 0 0 2 1 1 13 1 6 5
2022/202371 5 3 4 10 0 11 0 2 18 7 10 1
2023/2024254 16 3 13 19 18 27 2 13 1 71 25 46
2024/20251.356 151 76 42 12 39 50 200 67 274 96 115 234
2025/20264.071 213 343 198 478 337 303 849 436 469 445 0 0
Totale 5.826